Skip to main content

Table 2 Demographics and outcomes of the sepsis cohort and comparisons between 30-day non-survivors and survivors

From: Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness

  Sepsis cohort Non-survivors Survivors p value
Number, n (% of Sepsis cohort) 632 (100) 174 (27.5) 458 (72.5)  
Age in years, median (IQR) 69 (61–76) 73 (66–79) 68 (59–75) < 0.001
Female sex, n (%) 251 (39.7) 61 (35.1) 190 (41.5) 0.17
Body mass index (n = 588), median (IQR) 26.6 (22.9–30.7) 26.7 (23.3–31.2) 26.3 (21.8–30.5) 0.11
Comorbidities
None of those listed below, n (%) 173 (27.4) 46 (26.4) 127 (27.7) 0.74
Cardiovascular disease, n (%) 313 (49.5) 87 (50) 226 (49) 0.95
Respiratory disease, n (%) 156 (24.7) 47 (27) 109 (23.8) 0.46
Hepatic disease, n (%) 32 (5) 12 (6.9) 20 (4.4) 0.27
Renal disease, n (%) 63 (10.0) 18 (10.3) 45 (9.8) 0.96
Cancer, n (%) 109 (17.3) 37 (21.3) 72 (15.7) 0.13
Haematological disease, n (%) 47 (7.4) 17 (9.8) 30 (6.6) 0.23
Immunosuppression, n (%) 126 (19.9) 41 (23.6) 85 (18.6) 0.20
Diabetes, n (%) 167 (26.4) 40 (23.0) 127 (27.7) 0.27
Modified Charlson comorbidity index, median (IQR) 1 (0–2) 2 (0–2) 1 (0–2) 0.54
Department of origin
Emergency department/out of hospital, n (%) 276 (43.7) 62 (35.6) 214 (46.7) 0.012
Hospital ward, n (%) 282 (44.6) 87 (50) 195 (42.6) 0.094
Intermediate, n (%) 32 (5.1) 13 (7.5) 19 (4.1) 0.089
Operating room/postoperative ward, n (%) 42 (6.6) 12 (6.9) 30 (6.6) 0.88
Organ dysfunction and illness severity on ICU admission
SAPS3 score, median (IQR) 66 (57–77) 76 (66–82) 63 (56–73) < 0.001
SAPS3 EMR30-day, median (IQR) 29.9 (14.8–53) 50.9 (29.9–62.7) 24.2 (13.5–44.5) < 0.001
SOFA score, median (IQR) 7 (5–10) 9 (6–11) 7 (5–9) < 0.001
Cardiovascular SOFA score (n = 625), median (IQR) 3 (0–4) 3 (1–4) 3 (0–4) 0.037
Septic shock, n (%) 267 (42.2) 82 (47.1) 185 (40.4) 0.15
Outcomes
ICU length of stay in days, median (IQR) 2.5 (1.1–5.5) 2.7 (1.2–6.2) 2.4 (1–4.9) 0.16
CRRT use during ICU stay, n (%) 96 (15.2) 38 (21.8) 58 (12.7) 0.006
Biomarkers
bio-ADM pg/mL, median (IQR) 74 (42–145) 93 (51–173) 70 (39–131) < 0.001
bio-ADM > 70 pg/mL, n (%) 333 (52.7) 104 (59.8) 229 (50) 0.035
Lactate (n = 626) mmol/L, median (IQR) 2.8 (1.5–4.9) 3.3 (1.7–5.7) 2.5 (1.4–4.6) 0.002
CRP (n = 600) mg/L, median (IQR) 113 (35–241) 143 (47–238) 102 (32–242) 0.13
  1. Data regarding general characteristics, outcomes, organ dysfunction and illness severity are presented. Non-survivors were compared to survivors, and the p values refer to that comparison. Proportions (%) are within their subgroups unless otherwise specified. IQR: interquartile range; SAPS3: Simplified Acute Physiology Score III; EMR30-day: estimated 30-day mortality risk; SOFA: Sequential Organ Failure Assessment; ICU: intensive care unit; CRRT: continuous renal replacement therapy; bio-ADM: circulating bioactive adrenomedullin